Table 1.
Baseline characteristics of patients with COVID-19 infection.
| Whole cohort (n = 41) | No follow-up-cohort (n = 28) | Follow-up cohort (n = 13) | P follow-up vs. no follow-up | ||||
|---|---|---|---|---|---|---|---|
| Age (years, (median, [IQR])) | 67 | [56.5–76.5] | 69.5 | [59–78] | 60 | [53–66.5] | 0.019 |
| Gender, male (n, %) | 35 | 85.4% | 26 | 92.9% | 9 | 69.2% | ns |
| BMI, kg/m2 (median, [IQR]) | 28.0 | [25–32.7] | 27.8 | [24.3–31.1] | 29.6 | [27.8–33.5] | ns |
| Duration of ICU stay, days (median, [IQR]) | 39.0 | [24–52.5] | 28.5 | [24–47.5] | 46 | [30–62] | ns |
| Death during ICU stay (n, %) | 11 | 26.8% | 11 | 39.3% | |||
| Thromboembolic events (n, %) | 24 | 58.5% | 15 | 53.6% | 9 | 69.2% | ns |
| Intubation (n, %) | 36 | 87.8% | 25 | 89.3% | 11 | 84.6% | ns |
| ECMO (n, %) | 10 | 24.4% | 5 | 17.9% | 5 | 38.5% | ns |
| CRRT (n, %) | 22 | 53.7% | 13 | 46.4% | 9 | 69.2% | ns |
| SOFA-Score (median, [IQR]) | 9 | [6.5–11.5] | 8.5 | [6.25–11] | 10 | [6.25–12.0] | ns |
| SIC-Score (median, [IQR]) | 3 | [2–4] | 3 | [2–4] | 3 | [2–4] | ns |
| APACHE-Score (median, [IQR]) | 28 | [22–33] | 26 | [22–32] | 31.0 | [25.5–34] | ns |
| Follow up days | 100 | [63.5–108.50] | |||||
| Preexisting conditions | |||||||
| Coronary artery disease (n, %) | 9 | 22% | 7 | 25% | 2 | 15.4% | ns |
| Hypertension (n, %) | 28 | 68.3% | 18 | 64.3% | 10 | 76.9% | ns |
| Diabetes mellitus/insulin resistance (n, %) | 13 | 31.7% | 8 | 28.6 | 5 | 38.5% | ns |
| Chronic kidney disease (n, %) | 7 | 17.1% | 5 | 17.9% | 2 | 15.4% | ns |
| Chronic dialysis (n, %) | 1 | 2.4% | 1 | 3.6% | 0 | 0% | ns |
| Lung disease (n, %) | 10 | 24.4% | 7 | 25% | 3 | 23.1% | ns |
ECMO Extracorporeal membrane oxygenation, SOFA sequential organ failure assessment, CRRT continuous renal replacement therapy, SIC Sepsis-Induced Coagulopathy Score, APACHE acute physiology and chronic health evaluation.